On 27 May 2026, Sihuan Pharmaceutical purchased 8.00 million shares on the open market under its 2022 Share Award Scheme, representing approximately 0.0877% of the company’s issued share capital (excluding treasury shares). The average purchase price was HK$1.0052 per share, implying a total consideration of roughly HK$8.04 million.

The board views the transaction as a tool to enhance long-term incentives and retain key personnel, aligning with the group’s recent transition to profitable growth. In FY 2025, Sihuan Pharmaceutical recorded revenue of RMB2.62 billion, a 37.70% year-on-year increase, and swung to a profit of RMB185.40 million.

Medical aesthetics has emerged as the group’s primary revenue driver, generating RMB1.49 billion—up 99.60% year-on-year—and contributing 57% of total revenue, surpassing the 50% threshold for the first time. The segment’s performance reflects rapid commercialization of self-developed regenerative products and accelerated international expansion through the investment in Swiss firm Suisselle.

Meanwhile, the innovative drug division more than doubled revenue year-on-year, entering what management describes as a “full-scale commercialization harvest period” with ongoing progress in R&D, product launches and National Reimbursement Drug List inclusion.

Management asserts that the latest share repurchase fortifies employee alignment at a pivotal juncture of sustained high-growth momentum, supporting the execution of its dual-engine strategy spanning medical aesthetics and biopharmaceuticals.